Table 1.

Pharmacological characteristics of SGLT2 inhibitors available in the market.

SGLT2 inhibitors	Therapeutic indication	Dosing	Age	Type of therapy
Canagliflozin	Type 2 diabetes mellitus	100 mg once a day	Adult patients	Monotherapy or association
Dapagliflozin	Type 2 diabetes mellitus	10 mg once a day	Adult patients; children from	Monotherapy or association
	Heart failure	10 mg once a day	10 years of age (only for type 2
	Chronic kidney disease	10 mg once a day	diabetes mellitus)
Empagliflozin	Type 2 diabetes mellitus	10 mg once a day	Adult patients	Monotherapy or association
	Heart failure	10 mg once a day
Ertugliflozin	Type 2 diabetes mellitus	5 mg or 10 mg once a day	Adult patients	Monotherapy or association
Sotagliflozin	Type 1 diabetes mellitus	200 mg or 400 mg once a day	Adult patients	Monotherapy or association